Effects of MDM2, MDM4and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Fang, Shenying ^a   Krahe, Ralf ^a   Lozano, Guillermina ^a   Han, Younghun ^a   Chen, Wei ^a   Post, Sean M ^a   Zhang, Baili ^a   Wilson, Charmaine D ^a   Bachinski, Linda L ^a   Strong, Louise C ^a   Amos, Christopher I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADULT; ARTICLE; CANCER RISK; CODON; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM; UNITED STATES;

ADOLESCENT; ADULT; CODON; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES; YOUNG ADULT;

EID: 77956499678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010813     Document Type: Article

References (23)

1. Jin S, Levine AJ (2001) The p53 functional circuit. J Cell Sci 114: 4139-4140.
2. Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72: 975-983.
3. Malkin D (1994) P53 and the Li-Fraumeni syndrome. Biochim Biophys Acta 1198: 197-213.
4. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Jr., et al. (1991) Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51: 6094-6097.
5. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150: 1-13.
6. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Jr., Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10: 83-87.
7. Chen XM, Sturgis EM, El-Naggar AK, Wei QY, Li GJ (2008) Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis 29: 2120-2125. DOI 10.1093/carcin/bgn191.
8. Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athanasiadis G, et al. (2003) Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet 40: e34.
9. Di Como CJ, Gaiddon C, Prives C (1999) P73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells. Mol Cell Biol 19: 1438-1449.
10. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
11. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533.
12. Marcel V, Palmero EI, Falagan-Lotsch P, Martel-Planche G, Ashton-Prolla P, et al. (2009) TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. Journal of Medical Genetics 46: 766-772. DOI 10.1136/jmg.2009.066704.
13. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, et al. (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091-6096.
14. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, et al. (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death and Differentiation 13: 927-934. DOI 10.1038/sj.cdd.4401912.
15. Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, et al. (2009) Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A 106: 10236-10241. 0901298106 [pii];10.1073/pnas.0901298106 [doi].
16. Kulkarni DA, Vazquez A, Haffty BG, Bandera EV, Hu W, et al. (2009) A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis 30: 1910-1915. bgp224 [pii];10.1093/carcin/bgp224 [doi].
17. Ling DY, Wei LJ (1989) The Robust Inference for the Proportional Hazards Model. Journal of the American Statistical Association 84: 1074-1078.
18. Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC (1992) Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 51: 344-356.
19. Strong LC, Williams WR (1987) The genetic implications of long-term survival of childhood cancer. A conceptual framework. Am J Pediatr Hematol Oncol 9: 99-103.
20. Lathrop GM, Lalouel JM, Julier C, Ott J (1985) Multilocus Linkage Analysis in Humans - Detection of Linkage and Estimation of Recombination. American Journal of Human Genetics 37: 482-498.
21. Xiong X, Wang M, Wang L, Liu J, Zhao X, et al. (2009) Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 33: 1454-1458.
22. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110.
23. Dumont P, Leu JI, Della Pietra AC3, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.